Page 41 - 2019_07 resto del Mondo-web

In vivo manipulation of Treg cells
Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice. J Immunol. 2015;195(11):5203-5214.
52. Churlaud G, Jimenez V, Ruberte J, et al. Sustained stimulation and expansion of Tregs by IL2 control autoimmunity without impairing immune responses to infection, vaccination and cancer. Clin Immunol. 2014;151(2):114-126.
53. Johnson MC, Garland AL, Nicolson SC, et al. beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice. Diabetes. 2013;62(11):3775- 3784.
54. Ward NC, Yu A, Moro A, et al. IL-2/CD25: A Long-Acting Fusion Protein That Promotes Immune Tolerance by Selectively Targeting the IL-2 Receptor on Regulatory T Cells. J Immunol. 2018;201(9):2579-2592.
55. Bell CJ, Sun Y, Nowak UM, et al. Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun. 2015;56:66-80.
56. Stremska ME, Jose S, Sabapathy V, et al. IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury. J Am Soc Nephrol. 2017;28(9):2681-2693.
57. Miura Y, Thoburn CJ, Bright EC, et al. Association of Foxp3 regulatory gene expres- sion with graft-versus-host disease. Blood. 2004;104(7):2187-2193.
58. Zorn E, Kim HT, Lee SJ, et al. Reduced fre- quency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus- host disease. Blood. 2005;106(8):2903-2911.
59. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft- versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
60. Cohen JL, Trenado A, Vasey D, Klatzmann D, Salomon BL. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease. J Exp Med. 2002;196(3):401-406.
61. Edinger M, Hoffmann P, Ermann J, et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144- 1150.
62. Trenado A, Charlotte F, Fisson S, et al. Recipient-type specific CD4+CD25+ regula- tory T cells favor immune reconstitution and control graft-versus-host disease while main- taining graft-versus-leukemia. J Clin Invest. 2003;112(11):1688-1696.
63. Jones SC, Murphy GF, Korngold R. Post- hematopoietic cell transplantation control of graft-versus-host disease by donor CD425 T cells to allow an effective graft-versus- leukemia response. Biol Blood Marrow Transplant. 2003;9(4):243-256.
64. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
65. Hanash AM, Levy RB. Donor CD4+CD25+ T cells promote engraftment and tolerance following MHC-mismatched hematopoietic cell transplantation. Blood. 2005;105(4): 1828-1836.
66. Sykes M, Romick ML, Hoyles KA, Sachs DH. In vivo administration of interleukin 2 plus T cell-depleted syngeneic marrow pre- vents graft-versus-host disease mortality and
permits alloengraftment. J Exp Med.
1990;171(3):645-658.
67. Soiffer RJ, Murray C, Cochran K, et al.
Clinical and immunologic effects of pro- longed infusion of low-dose recombinant interleukin-2 after autologous and T-cell- depleted allogeneic bone marrow transplan- tation. Blood. 1992;79(2):517-526.
68. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994;84(3):964-971.
69. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance main- tained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-1164.
70. Zorn E, Mohseni M, Kim H, et al. Combined CD4+ donor lymphocyte infusion and low- dose recombinant IL-2 expand FOXP3+ reg- ulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(3):382- 388.
71. Koreth J, Matsuoka K, Kim HT, et al. Interleukin-2 and regulatory T cells in graft- versus-host disease. N Engl J Med. 2011;365(22):2055-2066.
72. Matsuoka K, Koreth J, Kim HT, et al. Low- dose interleukin-2 therapy restores regulato- ry T cell homeostasis in patients with chron- ic graft-versus-host disease. Sci Transl Med. 2013;5(179):179ra143.
73. Matsuoka KI. Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspec- tives. Int J Hematol. 2018;107(2):130-137.
74. Kennedy-Nasser AA, Ku S, Castillo-Caro P, et al. Ultra low-dose IL-2 for GVHD prophy- laxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regu- latory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res. 2014;20(8):2215-2225.
75. Kim N, Jeon YW, Nam YS, et al. Therapeutic potential of low-dose IL-2 in a chronic GVHD patient by in vivo expansion of regu- latory T cells. Cytokine. 2016;78:22-26.
76. Zhao XY, Zhao XS, Wang YT, et al. Prophylactic use of low-dose interleukin-2 and the clinical outcomes of hematopoietic stem cell transplantation: A randomized study. Oncoimmunology. 2016;5(12): e1250992.
77. Shatry A, Levy RB. In situ activation and expansion of host tregs: a new approach to enhance donor chimerism and stable engraft- ment in major histocompatibility complex- matched allogeneic hematopoietic cell trans- plantation. Biol Blood Marrow Transplant. 2009;15(7):785-794.
78. Shatry A, Chirinos J, Gorin MA, Jones M, Levy RB. Targeting Treg cells in situ: emerg- ing expansion strategies for (CD4(+)CD25(+)) regulatory T cells. Biol Blood Marrow Transplant. 2009;15(10): 1239-1243.
79. Perol L, Martin GH, Maury S, Cohen JL, Piaggio E. Potential limitations of IL-2 admin- istration for the treatment of experimental acute graft-versus-host disease. Immunol Lett. 2014;162(2 Pt B):173-184.
80. Shin HJ, Baker J, Leveson-Gower DB, et al. Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells. Blood. 2011;118(8):2342-2350.
81. Pidala J, Kim J, Jim H, et al. A randomized phase II study to evaluate tacrolimus in com-
bination with sirolimus or methotrexate after allogeneic hematopoietic cell transplan- tation. Haematologica. 2012;97(12):1882- 1889.
82. Betts BC, Pidala J, Kim J, et al. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017;102(5):948-957.
83. Xie Y, Wu M, Song R, et al. A glucocorticoid amplifies IL-2-induced selective expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells in vivo and suppresses graft-versus-host dis- ease after allogeneic lymphocyte transplanta- tion. Acta Biochim Biophys Sin (Shanghai). 2009;41(9):781-791.
84. Ito S, Bollard CM, Carlsten M, et al. Ultra- low dose interleukin-2 promotes immune- modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther. 2014;22(7):1388-1395.
85. Croft M, Benedict CA, Ware CF. Clinical tar- geting of the TNF and TNFR superfamilies. Nat Rev Drug Discov. 2013;12(2):147-168.
86. Salomon BL, Leclerc M, Tosello J, et al. Tumor Necrosis Factor alpha and Regulatory T Cells in Oncoimmunology. Front Immunol. 2018;9:444.
87. Mancusi A, Piccinelli S, Velardi A, Pierini A. The Effect of TNF-alpha on Regulatory T Cell Function in Graft-versus-Host Disease. Front Immunol. 2018;9:356.
88. Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ. Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regu- latory cells. J Immunol. 2007;179(1):154-161.
89. Chen X, Subleski JJ, Kopf H, et al. Cutting edge: expression of TNFR2 defines a maxi- mally suppressive subset of mouse CD4+CD25+FoxP3+ T regulatory cells: applicability to tumor-infiltrating T regulato- ry cells. J Immunol. 2008;180(10):6467-6471.
90. Grinberg-Bleyer Y, Saadoun D, Baeyens A, et al. Pathogenic T cells have a paradoxical pro- tective effect in murine autoimmune dia- betes by boosting Tregs. J Clin Invest. 2010;120(12):4558-4568.
91. Myers L, Joedicke JJ, Carmody AB, et al. IL- 2-independent and TNF-alpha-dependent expansion of Vbeta5+ natural regulatory T cells during retrovirus infection. J Immunol. 2013;190(11):5485-5495.
92. Housley WJ, Adams CO, Nichols FC, et al. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo func- tion. J Immunol. 2011;186(12):6779-6787.
93. Tsakiri N, Papadopoulos D, Denis MC, Mitsikostas DD, Kollias G. TNFR2 on non- haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE. Eur J Immunol. 2012;42(2):403-412.
94. Schmid T, Falter L, Weber S, et al. Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation. Front Immunol. 2017;8:1471.
95. Lamontain V, Schmid T, Weber-Steffens D, et al. Stimulation of TNF receptor type 2 expands regulatory T cells and ameliorates established collagen-induced arthritis in mice. Cell Mol Immunol. 2019;16(1):65-74.
96. Pierini A, Strober W, Moffett C, et al. TNF- alpha priming enhances CD4+FoxP3+ regu- latory T-cell suppressive function in murine GVHD prevention and treatment. Blood. 2016;128(6):866-871.
97. Leclerc M, Naserian S, Pilon C, et al. Control of GVHD by regulatory T cells depends on TNF produced by T cells and TNFR2 expressed by regulatory T cells. Blood. 2016;128(12):1651-1659.
98. Chopra M, Biehl M, Steinfatt T, et al. Exogenous TNFR2 activation protects from
haematologica | 2019; 104(7)
1319